Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tricida, Inc. (TCDA) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tricida, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1595585.
Total stock buying since 2018: $103,848,416.
Total stock sales since 2018: $202,439,808.
Total stock option exercises since 2018: $554,369.
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2022 | 4,442,691 | $45,021,937 | 21,412,395 | $13,227,475 | 0 | $0 |
2021 | 0 | $0 | 274,900 | $1,783,486 | 0 | $0 |
2020 | 65,000 | $1,375,018 | 157,750 | $3,859,726 | 51,750 | $89,417 |
2019 | 500,000 | $17,862,813 | 4,657,462 | $182,830,316 | 382,316 | $453,552 |
2018 | 2,080,792 | $39,588,648 | 29,651 | $738,805 | 14,251 | $11,400 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2022-11 | 0 | $0 | 20,721,357 | $4,445,306 | 0 | $0 |
2022-10 | 1,467,254 | $16,565,726 | 360,000 | $4,433,398 | 0 | $0 |
2022-09 | 1,091,775 | $10,230,272 | 0 | $0 | 0 | $0 |
2022-08 | 0 | $0 | 284,939 | $3,846,641 | 0 | $0 |
2022-07 | 425,872 | $4,020,543 | 0 | $0 | 0 | $0 |
2022-06 | 1,457,790 | $14,205,396 | 0 | $0 | 0 | $0 |
2022-04 | 0 | $0 | 46,099 | $502,130 | 0 | $0 |
2021-12 | 0 | $0 | 36,803 | $298,074 | 0 | $0 |
2021-11 | 0 | $0 | 137,097 | $846,042 | 0 | $0 |
2021-10 | 0 | $0 | 5,000 | $21,100 | 0 | $0 |
2021-09 | 0 | $0 | 5,000 | $21,150 | 0 | $0 |
2021-08 | 0 | $0 | 5,000 | $19,818 | 0 | $0 |
2021-07 | 0 | $0 | 5,000 | $19,449 | 0 | $0 |
2021-06 | 0 | $0 | 5,000 | $23,900 | 0 | $0 |
2021-04 | 0 | $0 | 5,000 | $22,700 | 0 | $0 |
2021-03 | 0 | $0 | 5,000 | $23,950 | 0 | $0 |
2021-02 | 0 | $0 | 13,000 | $92,630 | 0 | $0 |
2021-01 | 0 | $0 | 53,000 | $394,673 | 0 | $0 |
2020-12 | 25,000 | $177,900 | 50,000 | $395,000 | 0 | $0 |
2020-07 | 0 | $0 | 8,000 | $213,920 | 0 | $0 |
2020-06 | 0 | $0 | 8,000 | $208,740 | 0 | $0 |
2020-05 | 35,000 | $1,049,818 | 12,250 | $374,617 | 4,250 | $12,473 |
2020-04 | 0 | $0 | 12,250 | $341,155 | 4,250 | $12,030 |
2020-03 | 5,000 | $147,300 | 22,250 | $676,862 | 14,250 | $23,667 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2022-11-25 | Orbimed Capital Gp V Llc | Sale | 3,629,226 | .22 | 798,429 |
2022-11-25 | Bonita David P | Sale | 3,629,226 | .22 | 798,429 |
2022-11-23 | Orbimed Capital Gp V Llc | Sale | 5,617,300 | .21 | 1,179,633 |
2022-11-23 | Bonita David P | Sale | 5,617,300 | .21 | 1,179,633 |
2022-11-23 | Alpern Robert J | Sale | 131,879 | .21 | 27,694 |
2022-11-22 | Orbimed Capital Gp V Llc | Sale | 1,034,421 | .22 | 227,572 |
2022-11-22 | Bonita David P | Sale | 1,034,421 | .22 | 227,572 |
2022-11-21 | Alpern Robert J | Sale | 27,584 | .23 | 6,344 |
2022-10-19 | Shah Nimish P (10% Owner) | Buy | 311,466 | 10.77 | 3,354,488 |
2022-10-18 | Shah Nimish P (10% Owner) | Buy | 40,400 | 11.98 | 483,992 |
2022-10-17 | Shah Nimish P (10% Owner) | Buy | 170,292 | 11.67 | 1,987,307 |
2022-10-13 | Sibling Capital Ventures Iii Llc (Other) | Sale | 29,332 | 11.99 | 351,690 |
2022-10-13 | Shah Nimish P (10% Owner) | Buy | 4,674 | 11.98 | 55,994 |
2022-10-12 | Sibling Capital Ventures Iii Llc (Other) | Sale | 212,283 | 12.53 | 2,659,905 |
2022-10-11 | Sibling Capital Ventures Iii Llc (Other) | Sale | 118,385 | 12.01 | 1,421,803 |
2022-10-11 | Shah Nimish P (10% Owner) | Buy | 25,000 | 11.85 | 296,250 |
2022-10-10 | Shah Nimish P (10% Owner) | Buy | 80,314 | 11.89 | 954,933 |
2022-10-07 | Shah Nimish P (10% Owner) | Buy | 28,900 | 12.00 | 346,800 |
2022-10-03 | Shah Nimish P (10% Owner) | Buy | 537,472 | 11.27 | 6,057,308 |
2022-09-29 | Shah Nimish P (10% Owner) | Buy | 336,374 | 9.92 | 3,336,830 |
2022-09-28 | Shah Nimish P (10% Owner) | Buy | 76,600 | 9.92 | 759,872 |
2022-09-27 | Shah Nimish P (10% Owner) | Buy | 115,000 | 9.38 | 1,078,700 |
2022-09-26 | Shah Nimish P (10% Owner) | Buy | 395,614 | 8.56 | 3,386,455 |
2022-08-16 | Sibling Capital Ventures Iii Llc (Other) | Sale | 32,800 | 13.59 | 445,752 |
2022-08-15 | Sibling Capital Ventures Iii Llc (Other) | Sale | 37,339 | 13.42 | 501,089 |
2022-08-12 | Sibling Capital Ventures Iii Llc (Other) | Sale | 214,800 | 13.50 | 2,899,800 |
2022-07-29 | Shah Nimish P (10% Owner) | Buy | 18,900 | 9.21 | 174,069 |
2022-07-25 | Shah Nimish P (10% Owner) | Buy | 29,199 | 8.95 | 261,331 |
2022-07-22 | Shah Nimish P (10% Owner) | Buy | 15,000 | 9.21 | 138,150 |
2022-07-21 | Shah Nimish P (10% Owner) | Buy | 30,000 | 9.59 | 287,700 |
2022-07-20 | Shah Nimish P (10% Owner) | Buy | 25,000 | 9.54 | 238,499 |
2022-07-19 | Shah Nimish P (10% Owner) | Buy | 25,000 | 9.47 | 236,750 |
2022-07-18 | Shah Nimish P (10% Owner) | Buy | 100,000 | 9.02 | 902,000 |
2022-07-14 | Shah Nimish P (10% Owner) | Buy | 36,717 | 9.85 | 361,662 |
2022-07-13 | Shah Nimish P (10% Owner) | Buy | 32,856 | 9.98 | 327,902 |
2022-07-12 | Shah Nimish P (10% Owner) | Buy | 25,000 | 9.81 | 245,250 |
2022-07-05 | Shah Nimish P (10% Owner) | Buy | 32,500 | 9.53 | 309,725 |
2022-07-01 | Shah Nimish P (10% Owner) | Buy | 55,700 | 9.65 | 537,505 |
2022-06-30 | Shah Nimish P (10% Owner) | Buy | 11,958 | 9.66 | 115,514 |
2022-06-29 | Shah Nimish P (10% Owner) | Buy | 16,546 | 9.93 | 164,301 |
2022-06-28 | Shah Nimish P (10% Owner) | Buy | 34,366 | 9.71 | 333,693 |
2022-06-24 | Shah Nimish P (10% Owner) | Buy | 149,120 | 9.68 | 1,443,481 |
2022-06-23 | Shah Nimish P (10% Owner) | Buy | 200,000 | 10.50 | 2,100,000 |
2022-06-22 | Shah Nimish P (10% Owner) | Buy | 142,900 | 10.90 | 1,557,610 |
2022-06-16 | Shah Nimish P (10% Owner) | Buy | 5,951 | 9.69 | 57,665 |
2022-06-14 | Shah Nimish P (10% Owner) | Buy | 10,000 | 8.72 | 87,200 |
2022-06-13 | Shah Nimish P (10% Owner) | Buy | 50,000 | 8.14 | 407,000 |
2022-06-10 | Shah Nimish P (10% Owner) | Buy | 58,054 | 8.91 | 517,261 |
2022-06-09 | Shah Nimish P (10% Owner) | Buy | 109,100 | 8.97 | 978,627 |
2022-06-08 | Shah Nimish P (10% Owner) | Buy | 111,111 | 9.51 | 1,056,665 |
2022-06-07 | Shah Nimish P (10% Owner) | Buy | 367,813 | 9.89 | 3,637,670 |
2022-06-06 | Shah Nimish P (10% Owner) | Buy | 91,506 | 9.35 | 855,581 |
2022-06-03 | Shah Nimish P (10% Owner) | Buy | 37,643 | 9.33 | 351,209 |
2022-06-02 | Shah Nimish P (10% Owner) | Buy | 61,722 | 8.78 | 541,919 |
2022-04-28 | Sibling Capital Ventures Iii Llc (Other) | Sale | 11,804 | 10.61 | 125,240 |
2022-04-27 | Sibling Capital Ventures Iii Llc (Other) | Sale | 33,569 | 10.97 | 368,251 |
2022-04-26 | Sibling Capital Ventures Iii Llc (Other) | Sale | 726 | 11.90 | 8,639 |
2021-12-20 | Coufal Sandra I | Sale | 7,500 | 8.54 | 64,049 |
2021-12-16 | Coufal Sandra I | Sale | 931 | 8.38 | 7,801 |
2021-12-15 | Coufal Sandra I | Sale | 2,550 | 8.01 | 20,425 |
2021-12-08 | Coufal Sandra I | Sale | 500 | 8.00 | 4,000 |
2021-12-08 | Klaerner Gerrit (President and CEO) | Sale | 8,000 | 7.84 | 62,720 |
2021-12-07 | Coufal Sandra I | Sale | 15,722 | 8.03 | 126,247 |
2021-12-01 | Coufal Sandra I | Sale | 1,600 | 8.02 | 12,832 |
2021-11-18 | Coufal Sandra I | Sale | 800 | 7.72 | 6,176 |
2021-11-17 | Coufal Sandra I | Sale | 10,297 | 7.90 | 81,346 |
2021-11-15 | Klaerner Gerrit (President and CEO) | Sale | 126,000 | 6.02 | 758,520 |
2021-10-06 | Coufal Sandra I | Sale | 5,000 | 4.22 | 21,100 |
2021-09-10 | Coufal Sandra I | Sale | 5,000 | 4.23 | 21,150 |
2021-08-24 | Coufal Sandra I | Sale | 1,354 | 4.01 | 5,429 |
2021-08-20 | Coufal Sandra I | Sale | 546 | 3.87 | 2,113 |
2021-08-19 | Coufal Sandra I | Sale | 3,100 | 3.96 | 12,276 |
2021-07-20 | Coufal Sandra I | Sale | 2,500 | 4.02 | 10,049 |
2021-07-15 | Coufal Sandra I | Sale | 2,500 | 3.76 | 9,400 |
2021-06-08 | Coufal Sandra I | Sale | 5,000 | 4.78 | 23,900 |
2021-04-19 | Coufal Sandra I | Sale | 5,000 | 4.54 | 22,700 |
2021-03-10 | Coufal Sandra I | Sale | 5,000 | 4.79 | 23,950 |
2021-02-08 | Klaerner Gerrit (President and CEO) | Sale | 8,000 | 7.26 | 58,080 |
2021-02-03 | Coufal Sandra I | Sale | 5,000 | 6.91 | 34,550 |
2021-01-26 | Coufal Sandra I | Sale | 5,000 | 7.06 | 35,300 |
2021-01-14 | Klaerner Gerrit (President and CEO) | Sale | 1,655 | 7.18 | 11,882 |
2021-01-13 | Klaerner Gerrit (President and CEO) | Sale | 15,035 | 7.41 | 111,409 |
2021-01-12 | Klaerner Gerrit (President and CEO) | Sale | 9,821 | 7.65 | 75,130 |
2021-01-11 | Klaerner Gerrit (President and CEO) | Sale | 21,489 | 7.49 | 160,952 |
2020-12-14 | Coufal Sandra I | Sale | 50,000 | 7.90 | 395,000 |
2020-12-11 | Mckague Robert (EVP, General Counsel) | Buy | 10,000 | 7.62 | 76,200 |
2020-12-10 | Parker Geoffrey M. (CFO and EVP) | Buy | 15,000 | 6.78 | 101,700 |
2020-07-15 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 26.33 | 105,320 |
2020-07-01 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 27.15 | 108,600 |
2020-06-15 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 25.95 | 103,820 |
2020-06-01 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 26.23 | 104,920 |
2020-05-15 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 31.55 | 126,220 |
2020-05-12 | Parker Geoffrey M. (Chief Fin. Officer and EVP) | Buy | 2,742 | 30.88 | 84,659 |
2020-05-11 | Parker Geoffrey M. (Chief Fin. Officer and EVP) | Buy | 32,258 | 29.92 | 965,159 |
2020-05-08 | Otto Dawn Parsell (EVP, Clinical Development) | Sale | 3,000 | 31.98 | 95,940 |
2020-05-08 | Otto Dawn Parsell (EVP, Clinical Development) | Option Ex | 3,000 | 3.31 | 9,930 |
2020-05-05 | Otto Dawn Parsell (EVP, Clinical Development) | Sale | 1,250 | 30.18 | 37,725 |
2020-05-05 | Otto Dawn Parsell (EVP, Clinical Development) | Option Ex | 1,250 | 2.04 | 2,543 |
2020-05-01 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 28.68 | 114,732 |
2020-04-29 | Otto Dawn Parsell (EVP, Clinical Development) | Sale | 3,000 | 31.98 | 95,940 |
2020-04-29 | Otto Dawn Parsell (EVP, Clinical Development) | Option Ex | 3,000 | 3.31 | 9,930 |
2020-04-28 | Otto Dawn Parsell (EVP, Clinical Development) | Sale | 1,250 | 29.98 | 37,475 |
2020-04-28 | Otto Dawn Parsell (EVP, Clinical Development) | Option Ex | 1,250 | 1.68 | 2,100 |
2020-04-15 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 27.71 | 110,860 |
2020-04-06 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 24.22 | 96,880 |
2020-03-16 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 23.91 | 95,640 |
2020-03-10 | Parker Geoffrey M. (Chief Fin. Officer and EVP) | Buy | 5,000 | 29.46 | 147,300 |
2020-03-02 | Otto Dawn Parsell (EVP, Clinical Development) | Sale | 4,250 | 31.93 | 135,702 |
2020-03-02 | Otto Dawn Parsell (EVP, Clinical Development) | Option Ex | 4,250 | 3.31 | 14,067 |
2020-03-02 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 31.53 | 126,120 |
2020-03-02 | Hejlek Edward J (EVP, General Counsel & Secy.) | Sale | 10,000 | 31.94 | 319,400 |
2020-03-02 | Hejlek Edward J (EVP, General Counsel & Secy.) | Option Ex | 10,000 | .96 | 9,600 |
2020-02-18 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 36.10 | 144,400 |
2020-02-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 500 | 38.91 | 19,455 |
2020-02-05 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 500 | 1.68 | 840 |
2020-02-03 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 4,250 | 36.72 | 156,072 |
2020-02-03 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 4,250 | 3.31 | 14,067 |
2020-02-03 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 36.13 | 144,520 |
2020-02-03 | Hejlek Edward J (SVP, General Counsel & Secy.) | Sale | 10,000 | 36.13 | 361,300 |
2020-02-03 | Hejlek Edward J (SVP, General Counsel & Secy.) | Option Ex | 10,000 | .96 | 9,600 |
2020-01-15 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 35.26 | 141,040 |
2020-01-02 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 4,250 | 37.02 | 157,335 |
2020-01-02 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 4,250 | 1.68 | 7,140 |
2020-01-02 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 37.56 | 150,260 |
2020-01-02 | Hejlek Edward J (SVP, General Counsel & Secy.) | Sale | 10,000 | 37.51 | 375,050 |
2020-01-02 | Hejlek Edward J (SVP, General Counsel & Secy.) | Option Ex | 10,000 | .96 | 9,600 |
2019-12-26 | Hejlek Edward J (SVP, General Counsel & Secy.) | Option Ex | 4,200 | .96 | 4,032 |
2019-12-23 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 3,000 | 38.91 | 116,715 |
2019-12-23 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 3,000 | 1.20 | 3,600 |
2019-12-20 | Hejlek Edward J (SVP, General Counsel & Secy.) | Sale | 15,000 | 38.17 | 572,550 |
2019-12-20 | Hejlek Edward J (SVP, General Counsel & Secy.) | Option Ex | 15,000 | .96 | 14,400 |
2019-12-18 | Klaerner Gerrit (President and CEO) | Sale | 31,750 | 39.10 | 1,241,425 |
2019-12-11 | Klaerner Gerrit (President and CEO) | Sale | 7,572 | 43.60 | 330,139 |
2019-12-11 | Orbimed Capital Gp V Llc | Sale | 1,500,000 | 40.00 | 60,000,000 |
2019-12-11 | Bonita David P | Sale | 1,500,000 | 40.00 | 60,000,000 |
2019-12-10 | Coufal Sandra I | Sale | 2,333 | 43.23 | 100,843 |
2019-12-10 | Klaerner Gerrit (President and CEO) | Sale | 3,948 | 43.28 | 170,869 |
2019-12-02 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 39.49 | 157,960 |
2019-11-29 | Klaerner Gerrit (President and CEO) | Sale | 4,000 | 39.80 | 159,200 |
2019-11-26 | Otto Dawn Parsell (Sr VP, Clinical Development) | Sale | 5,746 | 39.60 | 227,541 |
2019-11-26 | Otto Dawn Parsell (Sr VP, Clinical Development) | Option Ex | 5,746 | 1.62 | 9,325 |
2019-11-26 | Alpern Robert J | Sale | 1,000 | 39.59 | 39,590 |
2019-11-22 | Sibling Capital Ventures Ii Llc (Other) | Sale | 180,864 | 40.85 | 7,388,294 |
2019-11-22 | Coufal Sandra I | Sale | 180,864 | 40.85 | 7,388,294 |
2019-11-21 | Sibling Capital Ventures Ii Llc (Other) | Sale | 190,682 | 40.80 | 7,780,397 |
2019-11-21 | Coufal Sandra I | Sale | 190,682 | 40.80 | 7,780,397 |
2019-11-20 | Sibling Capital Ventures Ii Llc (Other) | Sale | 110,585 | 39.89 | 4,411,014 |
2019-11-20 | Coufal Sandra I | Sale | 112,818 | 40.00 | 4,512,720 |
2019-11-20 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Sale | 814 | 40.81 | 33,219 |
2019-11-20 | Stahl Wilhelm (Chief Tech Officer & Sr. VP) | Option Ex | 814 | 1.68 | 1,367 |
Insider trading activities including stock purchases, stock sales, and option exercises of TCDA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tricida, Inc. (symbol TCDA, CIK number 1595585) see the Securities and Exchange Commission (SEC) website.